NYSE:LH - Laboratory Corp. of America Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$187.21 +1.21 (+0.65 %)
(As of 07/16/2018 07:44 AM ET)
Previous Close$186.00
Today's Range$185.55 - $187.57
52-Week Range$146.68 - $190.35
Volume390,327 shs
Average Volume650,848 shs
Market Capitalization$19.08 billion
P/E Ratio19.50
Dividend YieldN/A
Laboratory Corp. of America logoLaboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. The company also provides specialty testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, medical drug monitoring, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides drug development solutions and laboratory testing services; and testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests. Laboratory Corporation of America Holdings was founded in 1971 and is headquartered in Burlington, North Carolina.

Receive LH News and Ratings via Email

Sign-up to receive the latest news and ratings for LH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Medical laboratories
Sub-IndustryHealth Care Services


Debt-to-Equity Ratio0.91
Current Ratio1.38
Quick Ratio1.27


Trailing P/E Ratio19.50
Forward P/E Ratio16.21
P/E Growth1.68

Sales & Book Value

Annual Sales$10.44 billion
Price / Sales1.83
Cash Flow$15.0369 per share
Price / Cash12.45
Book Value$67.09 per share
Price / Book2.79


EPS (Most Recent Fiscal Year)$9.60
Net Income$1.27 billion
Net Margins11.52%
Return on Equity16.33%
Return on Assets6.49%


Outstanding Shares101,900,000
Market Cap$19,076.70

The Truth About Cryptocurrencies

Laboratory Corp. of America (NYSE:LH) Frequently Asked Questions

What is Laboratory Corp. of America's stock symbol?

Laboratory Corp. of America trades on the New York Stock Exchange (NYSE) under the ticker symbol "LH."

How were Laboratory Corp. of America's earnings last quarter?

Laboratory Corp. of America Holdings (NYSE:LH) issued its quarterly earnings data on Wednesday, April, 25th. The medical research company reported $2.78 EPS for the quarter, topping analysts' consensus estimates of $2.63 by $0.15. The medical research company had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.77 billion. Laboratory Corp. of America had a net margin of 11.52% and a return on equity of 16.33%. The firm's quarterly revenue was up 18.0% on a year-over-year basis. During the same period last year, the business posted $2.22 earnings per share. View Laboratory Corp. of America's Earnings History.

When is Laboratory Corp. of America's next earnings date?

Laboratory Corp. of America is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Laboratory Corp. of America.

What guidance has Laboratory Corp. of America issued on next quarter's earnings?

Laboratory Corp. of America updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share guidance of $11.30-11.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $11.54.

What price target have analysts set for LH?

16 brokerages have issued 12 month target prices for Laboratory Corp. of America's stock. Their predictions range from $172.00 to $220.00. On average, they expect Laboratory Corp. of America's share price to reach $192.3125 in the next year. This suggests a possible upside of 2.7% from the stock's current price. View Analyst Ratings for Laboratory Corp. of America.

What is the consensus analysts' recommendation for Laboratory Corp. of America?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Laboratory Corp. of America in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Laboratory Corp. of America's key competitors?

Who are Laboratory Corp. of America's key executives?

Laboratory Corp. of America's management team includes the folowing people:
  • Mr. Gary M. Huff, Chief Exec. Officer of Labcorp Diagnostics (Age 51)
  • Mr. David P. King, Chairman, CEO & Pres (Age 62)
  • Mr. Glenn A. Eisenberg, CFO & Exec. VP (Age 57)
  • Dr. Michelle Abelson, Laboratory Director of Operations
  • Mr. Edward T. Dodson, Chief Accounting Officer & Sr. VP (Age 65)

Has Laboratory Corp. of America been receiving favorable news coverage?

Media coverage about LH stock has been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Laboratory Corp. of America earned a news sentiment score of 0.10 on Accern's scale. They also gave news articles about the medical research company an impact score of 46.11 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Laboratory Corp. of America's major shareholders?

Laboratory Corp. of America's stock is owned by many different of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.18%), NN Investment Partners Holdings N.V. (0.12%), State of Alaska Department of Revenue (0.08%), Fisher Asset Management LLC (0.06%), First National Bank of Omaha (0.05%) and Contravisory Investment Management Inc. (0.04%). Company insiders that own Laboratory Corp. of America stock include Adam H Schechter, David P King, Dwight Gary Gilliland, Edward T Dodson, F Samuel Eberts III, Glenn A Eisenberg, Jean-Luc Belingard, Lance Berberian, Lisa J Uthgenannt, M Huff Gary, R Sanders Williams and Robert E Mittelstaedt Jr. View Institutional Ownership Trends for Laboratory Corp. of America.

Which major investors are selling Laboratory Corp. of America stock?

LH stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Farmers Trust Co., Fisher Asset Management LLC, JLB & Associates Inc., Gateway Investment Advisers LLC, Contravisory Investment Management Inc., American National Bank and Webster Bank N. A.. Company insiders that have sold Laboratory Corp. of America company stock in the last year include Adam H Schechter, David P King, Dwight Gary Gilliland, Edward T Dodson, F Samuel Eberts III, Glenn A Eisenberg, Lisa J Uthgenannt, M Huff Gary and R Sanders Williams. View Insider Buying and Selling for Laboratory Corp. of America.

Which major investors are buying Laboratory Corp. of America stock?

LH stock was acquired by a variety of institutional investors in the last quarter, including First National Bank of Omaha, State of Alaska Department of Revenue, First Citizens Bank & Trust Co., Daiwa SB Investments Ltd., Fjarde AP Fonden Fourth Swedish National Pension Fund, IFM Investors Pty Ltd, Pennsylvania Trust Co and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Laboratory Corp. of America.

How do I buy shares of Laboratory Corp. of America?

Shares of LH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Laboratory Corp. of America's stock price today?

One share of LH stock can currently be purchased for approximately $187.21.

How big of a company is Laboratory Corp. of America?

Laboratory Corp. of America has a market capitalization of $19.08 billion and generates $10.44 billion in revenue each year. The medical research company earns $1.27 billion in net income (profit) each year or $9.60 on an earnings per share basis. Laboratory Corp. of America employs 60,000 workers across the globe.

How can I contact Laboratory Corp. of America?

Laboratory Corp. of America's mailing address is 358 South Main Street, BURLINGTON NC, 27215. The medical research company can be reached via phone at 336-229-1127 or via email at [email protected]

MarketBeat Community Rating for Laboratory Corp. of America (NYSE LH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  371 (Vote Outperform)
Underperform Votes:  405 (Vote Underperform)
Total Votes:  776
MarketBeat's community ratings are surveys of what our community members think about Laboratory Corp. of America and other stocks. Vote "Outperform" if you believe LH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.